| Literature DB >> 35624767 |
Eleonora Russo1, Andrea Spallarossa1, Antonio Comite2, Marcello Pagliero2, Patrizia Guida3, Vittorio Belotti4, Debora Caviglia5, Anna Maria Schito5.
Abstract
The production of olive oil generates olive mill wastewater (OMW) which essentially derives from the processing, treatment and pressing of olives in mills. Traditional milling processes require a quantity of water varying between 40 and 120 L per quintal of pressed olives, generating a considerable amount of wastewater. It is thus necessary to reduce process water and enhance its use to implement the concept of a circular economy. To this end, our preliminary work was dedicated to water purification by means of suitable and efficient filtration systems. The microfiltered OMW was firstly concentrated through reverse osmosis. Then, an additional concentration step was carried out via vacuum membrane distillation using hydrophobic hollow fiber membranes. The application of the membrane-based processes allowed the recovery of a purified water and the concentration of valuable polyphenols in a smaller volume. The different fractions obtained from the purification have been tested for the determination of the antioxidant power (DPPH assay) and dosage of polyphenols (Folin-Ciocalteu assay) and were characterized using IR spectroscopy. All samples showed relevant antioxidant activity (percentage range: 10-80%) and total phenolic content in the 1.5-15 g GAE/L range. The obtained fractions were tested for their antimicrobial effect on numerous clinical isolates of Gram-positive and Gram-negative species, resistant and multi-resistant to current antibiotic drugs. OMW samples showed widespread activity against the considered (phyto)pathogens (MIC range 8-16 mg/mL) thus supporting the value of this waste material in the (phyto)pharmaceutical field.Entities:
Keywords: antibacterial activity; antioxidant activity; circular economy; membrane processes; olive mill wastewater; polyphenols
Year: 2022 PMID: 35624767 PMCID: PMC9137489 DOI: 10.3390/antiox11050903
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Olive oil production process.
Figure 2Schematic representation of OMW purification process. Analyzed samples: MF1: sample collected after the MF. ROp1: permeate sample collected in the middle of RO purification. ROp2: final permeate sample of RO purification. MD1: initial concentrate sample of VMD. MD2: final concentrate sample of VMD. MDd1: initial distillate sample of VMD. MDd2: final distillate sample of VMD.
Figure 3OMW conductivity against the volume concentration ratio achieved at each treatment step.
Conductivity of ROp and MDd samples.
| Sample | Conductivity (mS/cm) |
|---|---|
| ROp1 | 0.14 |
| ROp2 | 1.00 |
| MDd1 | 0.42 |
| MDd2 | 0.63 |
Figure 4EDX semiquantitative analysis of representative sample.
Figure 5OMW IR spectra before and after purification.
Total phenolic content analyzed in OMW using the Folin–Ciocalteu assay (mean value ± standard deviation (SD) of three independent experiments (n = 3), A = absorbance values). Numbers followed by different letters are statistically different at p < 0.001 (Tukey’s test).
| Sample Name | A (λ = 750 nm) | g GAE/L |
|---|---|---|
| MF1 | 0.188 | 1.304 ± 0.150 d |
| MF2 | 0.333 | 0.251 ± 0.056 e |
| ROP1 | 0.042 | 0.001 ± 0.001 e |
| ROP2 | 0.097 | 0.055 ± 0.006 e |
| RO1 | 0.131 | 8.292 ± 0.251 b |
| MD1 | 0.110 | 6.542 ± 0.227 c |
| MD2 | 0.216 | 15.375 ± 0.015 a |
| MDd1 | 0.180 | 0.012 ± 0.001 e |
| MDd2 | 0.150 | 0.010 ± 0.001 e |
Figure 6Gallic acid calibration curve (concentrations ranging from 20 to 80 mg/L).
Evaluation of antioxidant activity percent (AA%) using DPPH assay (mean value ± standard deviation (SD) of three independent experiments (n = 3)). Numbers followed by different letters are statistically different at p < 0.001 (Tukey’s test).
| Sample Name | A (517 nm) | DPPH% | AA% |
|---|---|---|---|
| MF1 | 0.861 | 88.95 ± 0.3 | 11.05 ± 0.3 e |
| MF2 | 0.893 | 92.25 ± 0.2 | 7.75 ± 0.2 f |
| ROP1 | 0.898 | 92.77 ± 0.4 | 7.23 ± 0.4 f |
| ROP2 | 0.708 | 73.14 ± 0.1 | 26.86 ± 0.1 d |
| RO1 | 0.633 | 65.39 ± 0.2 | 34.61 ± 0.2 c |
| MD1 | 0.514 | 53.10 ± 0.2 | 46.90 ± 0.2 b |
| MD2 | 0.17 | 17.56 ± 0.3 | 82.44 ± 0.3 a |
| MDd1 | 0.858 | 88.64 ± 0.5 | 11.36 ± 0.5 e |
| MDd2 | 0.864 | 89.26 ± 0.1 | 10.74 ± 0.1 e |
Figure 7Trolox calibration curve (concentrations ranging from 20 to 200 mg/L).
MIC and MBC values expressed as mg/mL of the seven OMW samples on the selected Gram-positive strains. Experiments were carried out in triplicate. The degree of concordance in all the experiments was 3/3. Variation among triplicate samples was less than 10%. MRSA: methicillin-resistant S. aureus strains; MRSE: methicillin-resistant S. epidermidis strains VRE: vancomycin-resistant isolates.
| MF1 | RO1 | ROP2 | MD1 | MD2 | MDd1 | MDd2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | |
|
| ||||||||||||||
| 17 MRSA | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 8 | 16 | 125 | >125 | 62 | >125 |
| 18 MRSA | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 16 | 8 | 16 | 125 | >125 | 62 | >125 |
| 187 MRSA | 125 | >125 | 31 | 31 | 125 | >125 | 16 | 31 | 8 | 16 | 125 | >125 | 62 | >125 |
| 188 MRSA | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 16 | 8 | 16 | 125 | >125 | 62 | >125 |
|
| ||||||||||||||
| 22 MRSE | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 16 | 8 | 16 | 125 | >125 | 62 | 125 |
| 180 MRSE | 62 | >125 | 16 | 16 | 125 | >125 | 16 | 16 | 8 | 16 | 62 | 125 | 62 | 62 |
| 181 MRSE | 62 | >125 | 16 | 16 | 125 | >125 | 16 | 16 | 8 | 8 | 125 | >125 | 62 | 125 |
| 222 MRSE | 125 | >125 | 16 | 16 | 125 | >125 | 16 | 16 | 16 | 16 | 125 | >125 | 62 | 125 |
|
| ||||||||||||||
| 1 VRE | 125 | >125 | 16 | 62 | 125 | >125 | 16 | 62 | 16 | 31 | 62 | >125 | 62 | >125 |
| 4 | 125 | >125 | 16 | 62 | 125 | >125 | 16 | 62 | 16 | 31 | 62 | >125 | 31 | >125 |
| 50 VRE | 125 | >125 | 16 | 62 | 125 | >125 | 16 | 62 | 16 | 31 | 62 | >125 | 62 | >125 |
| 365 VRE | 125 | >125 | 16 | 125 | 125 | >125 | 16 | 125 | 16 | 31 | 62 | >125 | 31 | >125 |
|
| ||||||||||||||
| 21 | 125 | >125 | 16 | 62 | 125 | >125 | 16 | 62 | 16 | 16 | 62 | >125 | 62 | >125 |
| 40 | 125 | >125 | 16 | 62 | 125 | >125 | 16 | 62 | 16 | 16 | 62 | >125 | 62 | >125 |
| 300 VRE | 125 | >125 | 16 | 62 | 125 | >125 | 16 | 62 | 16 | 16 | 62 | >125 | 62 | >125 |
| 362 VRE | 125 | >125 | 16 | 62 | 125 | >125 | 16 | 62 | 16 | 16 | 62 | >125 | 31 | >125 |
MIC and MBC values expressed as mg/mL of the seven OMW samples on the selected Gram-negative strains. Experiments were carried out in triplicate. The degree of concordance in all the experiments was 3/3. Variation among triplicate samples was less than 10%. C denotes resistance to colistin; * denotes a class A carbapenemase (KPC)-producing bacterium.
| MF1 | RO1 | ROP2 | MD1 | MD2 | MDd1 | MDd2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | |
|
| ||||||||||||||
| 403 | 62 | >125 | 16 | 31 | 62 | >125 | 16 | 31 | 8 | 16 | 62 | >125 | 31 | 125 |
| 432 | 62 | >125 | 16 | 31 | 62 | >125 | 16 | 31 | 8 | 16 | 62 | >125 | 31 | 125 |
| 265c | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 16 | 16 | 62 | >125 | 31 | 125 |
| 1 | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 16 | 16 | 62 | >125 | 31 | 125 |
| 2v | 62 | >125 | 16 | 31 | 62 | >125 | 16 | 31 | 8 | 16 | 62 | >125 | 31 | 125 |
| 19v | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 8 | 16 | 62 | >125 | 31 | 125 |
| 16b | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 16 | 16 | 62 | >125 | 31 | 125 |
| 12b | 62 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 8 | 16 | 62 | >125 | 31 | 125 |
| 8g | 125 | >125 | 16 | 31 | 62 | >125 | 16 | 31 | 8 | 16 | 62 | >125 | 31 | 125 |
|
| ||||||||||||||
| 245 | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 16 | 16 | 62 | 125 | 31 | 125 |
|
| ||||||||||||||
| 372 | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 16 | 31 | 62 | >125 | 31 | 125 |
|
| ||||||||||||||
| 374 | 125 | >125 | 16 | 31 | 125 | >125 | 16 | 31 | 16 | 16 | 62 | >125 | 62 | 125 |
|
| ||||||||||||||
| 375 * | 125 | >125 | 31 | 62 | 125 | >125 | 31 | 62 | 16 | 31 | 62 | >125 | 62 | 125 |
| 376 * | 62 | >125 | 16 | 62 | 62 | >125 | 16 | 62 | 8 | 31 | 62 | >125 | 62 | >125 |
| 377 * | 125 | >125 | 31 | 31 | 125 | >125 | 31 | 62 | 16 | 31 | 62 | >125 | 62 | >125 |
|
| ||||||||||||||
| 400 | 125 | >125 | 31 | 31 | 125 | >125 | 16 | 31 | 16 | 31 | 62 | >125 | 31 | 125 |
|
| ||||||||||||||
| 391 | 62 | >125 | 16 | 31 | 62 | >125 | 16 | 31 | 8 | 16 | 62 | >125 | 31 | 125 |
| 392 | 62 | >125 | 16 | 31 | 62 | >125 | 16 | 31 | 16 | 16 | 62 | >125 | 31 | 125 |
|
| ||||||||||||||
| 224 | 125 | >125 | 31 | 62 | 125 | >125 | 31 | 62 | 16 | 31 | 62 | >125 | 62 | >125 |
| 238 * | 125 | >125 | 31 | 62 | 125 | >125 | 31 | 62 | 16 | 31 | 62 | >125 | 62 | >125 |
| 4 | 125 | >125 | 31 | 62 | 125 | >125 | 31 | 62 | 16 | 31 | 62 | >125 | 62 | >125 |
|
| ||||||||||||||
| 266 | 62 | >125 | 16 | 31 | 62 | >125 | 16 | 31 | 8 | 31 | 62 | >125 | 31 | 125 |